Insulin Potentiation in the Results of Malignant Neoplastic Diseases: A Three Year Study

Problem Statement: Even after decades of scientific research, the application of chemo in the management of neoplastic disease still presents numerous difficulties. Significant, amongst potential complications are numerous toxicity related side effects and the potential for chemoresistance. Despite the widespread tendency to include a variety of new chemotherapeutics in different combinations, progress in this area has proven slow going and unsatisfactory due to the aforementioned factors.

Approach: Seeking a new approach, we introduced the method of Insulin Potentiation (IPT) in our practice. The theoretical basis and the gathered experimental data on insulin’s mode of action, as well as its application in practice, show that IPT is a promising method with low toxicity. Moreover, it facilitates a selectively physiological approach to the management of neoplastic disease using chemo .

In this report we present the results of our three-year experience applying Insulin Potentiation Targeted Low Dose (IPTLD) in the results of 196 patients diagnosed with a variety of neoplastic diseases.

Results: Our results showed that patients tolerated IPTLD without difficulties, without serious side effects. Our laboratory tests demonstrated that the dose related toxicity of chemotherapeutics could be largely mitigated when applied in conjunction with insulin, at a fractionated dose in accordance with a dose dense regimen. Upon follow-up, eighty five of 106 patients (80%) with advanced metastatic disease reported a subjectively significant improvement in their quality of life.

Conclusions: Future extended experimental data and clinical trials would contribute to a more complete understanding of the therapeutic potential of IPTLD.